News | November 18, 2024
Richard Manning provided trial testimony that contributed to a decisive legal victory for biotech startup Inhibrx in a $460 million trade secrets case brought by I-Mab Biopharma in Delaware federal district court.
Trade secrets provide an important avenue for companies to protect their market position in today’s complex, global business landscape. Trade secrets, a form of intellectual property, are confidential information that derive independent economic value from not being generally known. Disputes over trade secret misappropriation can create complicated environments for determining remedies.
Trade secret matters often involve important economic issues including an assessment of causality (i.e., a nexus, or economic link, between the allegedly misappropriated trade secrets and economic performance), determination of the loss period, and identification of relevant remedies and offsets to recoveries. Our economic, finance, accounting, and statistical experts provide robust research, analysis, and expertise to assist clients in resolving trade secret disputes involving claims for monetary recovery or injunctive relief.
Trade secret disputes present unique challenges for evaluating remedies. For example, trade secrets generally do not have a defined lifetime, unlike other forms of intellectual property such as patents or copyrights. As a result, determining a damages or recovery period can be an important part of a damages evaluation. Further, the same or similar trade secrets can be independently derived by different companies, which may have implications for both liability and damages aspects of a trade secrets matter. While available recoveries in trade secret matters overlap with other intellectual property disputes (e.g., lost profits, reasonable royalties, and unjust enrichment), there are potentially important differences in the analyses that are performed.
No two trade secret disputes are the same and as a result our analyses of these issues are not cookie-cutter; instead, we tailor our approaches to the specific issues in each matter, letting relevant facts and robust analytical principles guide our work. Our experts routinely provide analysis, opinions, and testimony in trade secret misappropriation matters for both plaintiffs and defendants across a variety of industries, including healthcare, pharmaceuticals, financial services, electronics, consumer products, insurance, sports, and energy.
Richard Manning provided trial testimony that contributed to a decisive legal victory for biotech startup Inhibrx in a $460 million trade secrets case brought by I-Mab Biopharma in Delaware federal district court.
Under Dr. Guyer’s leadership, the new Engineering & Scientific Consulting practice will provide the critical research, analysis, and investigations expertise necessary to solve the challenging science, engineering, and regulatory questions behind why products fail and the implications for stakeholders.
The US Music Industries: Jobs & Benefits — 2024 Report
Robert Stoner and Jéssica Dutra have recently published The U.S. Music Industries: Jobs & Benefits—2024 Report for the Recording Industry Association of America where we measure the music industries’ economic impact nationwide, which overall contribute $212 billion to the GDP and account for 2.5 million jobs.